nach oben

Current Rheumatology Reports

Erschienen in:

01.12.2010

Behçet’s Syndrome

verfasst von: Yusuf Yazici, Sebahattin Yurdakul, Hasan Yazici

Erschienen in: Current Rheumatology Reports | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Behçet’s syndrome is a systemic vasculitis with an unknown etiology affecting the small and large vessels of the venous and arterial systems. At least two clusters of disease expression have been described. The first includes superficial vein thrombosis, deep vein thrombosis, and dural sinus thrombi. The second includes acne, arthritis, and enthesitis. The presence of these clusters suggests there may be more than one disease mechanism operative in this complex disorder. Recent European League Against Rheumatism guidelines are useful for the management of the disease in organ systems distinct from the vascular, neurological, and gastrointestinal systems. This is because of a lack of controlled studies evaluating such vascular, neurological, and gastrointestinal complications.

Behçet H: Uber rezidivierende, aphthose, dürch ein Virus verursachte Geshwure am Munde, am Auge und an den Genitalien [in German]. Dematologische Wochenschrift 1937, 36:1152–1157.

Yurdakul S, Hamuryudan V, Fresko I, et al.: Behçet’s syndrome. In Rheumatology, edn 4. Edited by Hochberg MC, Silman AJ, Smolen YS, et al. Philadelphia, PA: Mosby Elsevier; 2008:1561–1565.

Verity DH, Marr JE, Ohno S, et al.: Behçet’s disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 1999, 54:213–220.CrossRefPubMed

Demirhindi O, Yazici H, Binyildiz P, et al.: Silivri Fener koyu ve yoresinde Behçet hastaligi sikligi ve bu hastaligin toplum icinde taranabilmesinde kullanabilecek bir yontem [in Turkish]. Cerrahpasa Tip Fak Derg 1981, 12:509–514.

Yurdakul S, Gunaydin I, Tuzun Y, et al.: The prevalence of Behçet’s syndrome in a rural area in northern Turkey. J Rheumatol 1988, 15:820–822.PubMed

Ozen S, Karaaslan Y, Ozdemir O, et al.: Prevalence of juvenile chronic arthritis and familial Mediterranean fever in Turkey: a field study. J Rheumatol 1998, 25:2445–2449.PubMed

Jaber L, Milo G, Halpern GJ, et al.: Prevalence of Behçet’s disease in an Arab community in Israel. Ann Rheum Dis 2002, 61:365–366.CrossRefPubMed

Papoutsis NG, Abdel-Naser MB, Altenburg A, et al.: Prevalence of Adamantiades-Behçet’s disease in Germany and the municipality of Berlin: results of a nationwide survey. Clin Exp Rheumatol 2006, 24(5 Suppl 42):S125.PubMed

Shimizu T, Ehrlich GE, Inaba G, et al.: Behçet disease (Behçet syndrome). Semin Arthritis Rheum 1979, 8:223–260.CrossRefPubMed

10.

Yazici H, Chamberlain MA, Tuzun Y, et al.: A comparative study of the pathergy among Turkish and British patients with Behçet’s disease. Ann Rheum Dis 1984, 43:74–75.CrossRefPubMed

11.

Yazici H, Tuzun Y, Pazarli H, et al.: Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behçet’s syndrome. Ann Rheum Dis 1984, 43:783–789.CrossRefPubMed

12.

Mat C, Göksugur N, Engin B, et al.: The frequency of scarring after genital ulcers in Behçet’s syndrome: a prospective study. Int J Dermatol 2006, 45:554–556.CrossRefPubMed

13.

Ergun T, Gurbuz O, Dogusoy G, et al.: Histopathologic features of the spontaneous pustular lesions of Behçet’s syndrome. Int J Dermatol 1998, 37:194–196.CrossRefPubMed

14.

Tüzün Y, Yazici H, Pazarli H, et al.: The usefulness of the nonspecific skin hyperreactivity (the pathergy test) in Behçet’s disease in Turkey. Acta Derm Venereol 1979, 59:77–79.PubMed

15.

Mat C, Demirkesen C, Melikoglu M, et al.: Behçet’s syndrome. In Handbook of Systemic Autoimmune Diseases. The Skin in Autoimmune Diseases. Edited by Sarzi-Puttini P, Doria A, Girolomini G, Kuhn A. Philadelphia, PA: Elsevier; 2006:185–206.CrossRef

16.

Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al.: Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 2004, 138:373–380.CrossRefPubMed

17.

Yurdakul S, Yazici H, Tuzun Y, et al.: The arthritis of Behçet’s disease: a prospective study. Ann Rheum Dis 1983, 42:505–515.CrossRefPubMed

18.

Diri E, Mat C, Hamuryudan V, et al.: Papulopustular skin lesions are seen more frequently in patients with Behçet’s syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis 2001, 60:1074–1076.CrossRefPubMed

19.

Muftuoglu AU, Yurdakul S, Yazici H, et al.: Vascular involvement in Behçet disease: a review of 129 cases. In Recent Advances in Behcet Disease. Edited by Lehner T, Barnes CG. London: Royal Society of Medicine Services; 1986:255–260.

20.

Lie JT: Vascular involvement in Behçet’s disease: arterial and venous and vessels of all sizes. J Rheumatol 1992, 19:341–343.PubMed

21.

Hamuryudan V, Yurdakul S, Moral F, et al.: Pulmonary arterial aneurysms in Behçet’s syndrome: a report of 24 cases. Br J Rheumatol 1994, 33:48–51.CrossRefPubMed

22.

Seyahi E, Melikoglu M, Akman C, et al.: Pulmonary vascular involvement in Behçet’s syndrome (BS) [abstract]. Arthritis Rheum 2007, 56(Suppl):853.

23.

Seyahi E, Ugurlu S, Cumali R, et al.: Atherosclerosis in Behçet’s syndrome. Semin Arthritis Rheum 2008, 38:1–12.CrossRefPubMed

24.

Akman-Demir G, Serdaroglu P, Tasci B: Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain 1999, 122:2171–2182.CrossRefPubMed

25.

Webb CJ, Moots RJ, Swift AC: Ear, nose and throat manifestations of Behçet's disease: a review. J Laryngol Otol 2008, 122:1279–1283.CrossRefPubMed

26.

Korman U, Cantasdemir M, Kurugoglu S, et al.: Enteroclysis findings of intestinal Behcet disease: a comparative study with Crohn disease. Abdom Imaging 2003, 28:308–312.CrossRefPubMed

27.

Melikoglu M, Kural-Seyahi E, Tascilar K, et al.: The unique features of vasculitis in Behçet’s syndrome. Clin Rev Allergy Immunol 2008, 35:40–46.CrossRefPubMed

28.

Gül A, Inanç M, Ocal L, et al.: Familial aggregation of Behçet’s disease in Turkey. Ann Rheum Dis 2000, 59:622–625.CrossRefPubMed

29.

Gül A: Behçet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005, 4:81–83.CrossRefPubMed

30.

Yazici H, Fresko I: Behçet’s disease and other autoinflammatory conditions: what’s in a name? Clin Exp Rheumatol 2005, 23(4 Suppl 38):S1–S2.PubMed

31.

Tunc R, Saip S, Siva A, et al.: Cerebral venous thrombosis is associated with major vessel disease in Behçet’s syndrome. Ann Rheum Dis 2004, 63:1693–1694.CrossRefPubMed

32.

Hatemi G, Bahar H, Uysal S, et al.: The pustular skin lesions in Behcet’s syndrome are not sterile. Ann Rheum Dis 2004, 63:1450–1452.CrossRefPubMed

33.

Fresko I, Ugurlu S, Ozbakir F, et al.: Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behçet’s syndrome. Clin Exp Rheumatol 2005, 23(4 Suppl 38):S67–S70.PubMed

34.

Muftuoglu AU, Yazici H, Yurdakul S, et al.: Behçet’s disease. Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity. Int J Dermatol 1986, 25:235–239.CrossRefPubMed

35.

Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet 1990, 335:1078–1080.

36.

O’Neill TW, Rigby AS, Silman AJ, et al.: Validation of the International Study Group criteria for Behcet’s disease. Br J Rheumatol 1994, 33:115–117.CrossRefPubMed

37.

Yazici H, Seyahi E, Yurdakul S: Behçet’s syndrome is not so rare: why do we need to know? Arthritis Rheum 2008, 58:3640–3643.CrossRefPubMed

38.

• Kural-Seyahi E, Fresko I, Seyahi N, et al.: The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003, 82:60–76.CrossRef

39.

Aktulga E, Altac M, Muftuoglu A, et al.: A double blind study of colchicine in Behçet’s disease. Haematologica 1980, 65:399–402.PubMed

40.

Yurdakul S, Mat C, Tuzun Y, et al.: A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum 2001, 44:2686–2692.CrossRefPubMed

41.

Yazici H, Pazarli H, Barnes CG, et al.: A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 1990, 322:281–285.CrossRefPubMed

42.

Hamuryudan V, Ozyazgan Y, Hizli N, et al.: Azathioprine in Behçet’s syndrome: effects on long-term prognosis. Arthritis Rheum 1997, 40:769–774.CrossRefPubMed

43.

Masuda K, Nakajima A, Urayama A, et al.: Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet 1989, 333:1093–1096.CrossRef

44.

Hamuryudan V, Mat C, Saip S, et al.: Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 128:443–450.PubMed

45.

Alpsoy E, Durusoy C, Yilmaz E, et al.: Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002, 138:467–471.CrossRefPubMed

46.

Gueudry J, Wechsler B, Terrada C, et al.: Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol 2008, 146:837.e1–844.e1.CrossRef

47.

Sfikakis PP, Markomichelakis N, Alpsoy E, et al.: Anti-TNF therapy in the management of Behcet’s disease—review and basis for recommendations. Rheumatology (Oxford) 2007, 46:736–741.CrossRef

48.

Melikoglu M, Fresko I, Mat C, et al.: Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J Rheumatol 2005, 32:98–105.PubMed

49.

• Hatemi G, Silman A, Bang D, et al.: EULAR recommendations for the management of Behçet’s disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2008, 67:1656–1662. This is a very good review of the current information on treatment of BS.

Titel: Behçet’s Syndrome
verfasst von: Yusuf Yazici
Sebahattin Yurdakul
Hasan Yazici
Publikationsdatum: 01.12.2010
Verlag: Current Science Inc.
Erschienen in: Current Rheumatology Reports / Ausgabe 6/2010
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-010-0132-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

26.04.2024 | Hüft-TEP | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Behçet’s Syndrome

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2010

Is It All Central Sensitization? Role of Peripheral Tissue Nociception in Chronic Musculoskeletal Pain

Rheumatoid Vasculitis: Vanishing Menace or Target for New Treatments?

Variations in Brain Gray Matter Associated with Chronic Pain

Pulmonary Vasculitis: Clinical Presentation, Differential Diagnosis, and Management

ANCA-Associated Small Vessel Vasculitis: Clinical and Therapeutic Advances

Pathophysiology of ANCA-Associated Small Vessel Vasculitis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Update Innere Medizin